Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2020 Sep 11;11:576887. doi: 10.3389/fphar.2020.576887

Lipid Membranes as Key Targets for the Pharmacological Actions of Ginsenosides

Sandrine L Verstraeten 1,, Joseph H Lorent 1,2,, Marie-Paule Mingeot-Leclercq 1,*
PMCID: PMC7518029  PMID: 33041822

Abstract

In this review, we will focus on the activity of ginsenosides on membranes and their related effects, from physicochemical, biophysical, and pharmacological viewpoints. Ginsenosides are a class of saponins with a large structural diversity and a wide range of pharmacological effects. These effects can at least partly be related to their activity on membranes which results from their amphiphilic character. Some ginsenosides are able to interact with membrane lipids and associate into nanostructures, making them possible adjuvants for vaccines. They are able to modulate membrane biophysical properties such as membrane fluidity, permeability or the formation of lateral domains with some degree of specificity towards certain cell types such as bacteria, fungi, or cancer cells. In addition, they have shown antioxidant properties which protect membranes from lipid oxidation. They further displayed some activity on membrane proteins either through direct or indirect interaction. We investigate the structure activity relationship of ginsenosides on membranes and discuss the implications and potential use as anticancer, antibacterial, and antifungal agents.

Keywords: ginsenosides, biophysical membrane properties, lipid dynamics and membrane organization, anticancer, anti-infectious agents

Introduction

The plasma membrane is the interface between the inter- and intracellular spaces. A major function of the plasma membrane is to transmit signals from the exterior to the interior of the cell. This makes it a rational target for pharmacological agents that modulate signaling and subsequently provoke a physiological or cellular response (Lorent et al., 2013). The majority of drugs act on membrane proteins (Lorent et al., 2017); however, lipids are also important for signal transduction. Lipids can collectively form signaling platforms or lateral domains, which include or exclude certain types of proteins. Analysis of the plasma membrane lipidome has highlighted a great variety of membrane lipids (van Meer, 2005). However, it remains unknown whether each individual lipid has its own function or whether, collectively, lipids confer biophysical properties to the membrane, and hence modulate cellular functions.

Among the active ingredients of ginseng are saponins, most of which are glycosides of triterpenoid aglycones (Shin et al., 2015). Ginseng saponins, also called ginsenosides, are numerous with a high chemical variation, depending on the linkage position and numbers of sugars on the aglycone skeleton (He et al., 2018). Ginsenosides are membrane-active substances, which modulate membrane dynamics and lateral organization in domains (Kwon et al., 2008; Park et al., 2010; Lorent J. et al., 2014). Interestingly, the mechanism of action of most ginsenosides does not seem to involve the formation of pores or holes in the membrane, as observed for other saponins such as digitonin (Lorent J. H. et al., 2014) or α-hederin (Lorent et al., 2013), reducing the risk of hemolysis. The traditional use of ginseng suggests that ginsenosides are relatively safe in vivo and constitute interesting pharmacological agents. In this review, we will focus on the activity of ginsenosides on membranes and their related effects, from physicochemical, biophysical, and pharmacological viewpoints ( Table 1 ).

Table 1.

Interaction of ginsenosides with membranes and pharmacological consequences.

Direct effects of ginsenoside(s) Ginsenoside(s) Method Model Pharmacological consequence(s) References
Membrane dynamics
Compacts the hydrophobic membrane core Rh2 Fluorescence anisotropy of DPH B16 melanoma cells Induces flattening, increases adhesiveness to plastic surfaces,
agglutinability of B16 cells
(Ota et al., 1987)
Relaxes the interfacial packaging of the polar head of PL Rh2 Fluorescence anisotropy of DPH U937 leukemia cells Inactivates Akt and induces cancer cell apoptosis (Verstraeten et al., 2018)
Compacts the hydrophobic membrane core Rh2 Fluorescence anisotropy of DPH and TMA-DPH B16 melanoma cells Induces dendrite formation in melanoma cells (Jiang et al., 2010)
Increases membrane fluidity Rb2, Rc, Rd Re, Rf, Rg1, Rg2, Rh2, PPD Two-photon fluorescence microscopy with carboxy-laurdan HeLa cervical carcinoma cells Activates death receptors and induces cancer cells apoptosis (Yi et al., 2009)
Compacts the hydrophobic membrane core Rh1 Fluorescence anisotropy of DPH B16 melanoma cells Does not induce changes in cell morphology and exerts no effect on cell adhesiveness (Ota et al., 1987)
Compacts the hydrophobic membrane core Rg3 Fluorescence anisotropy of DPH Bovine chromaffin cells Inhibits catecholamine secretion from cells stimulated by acetylcholine (Tachikawa et al., 2001)
Compacts the hydrophobic membrane core and the interfacial packaging Rg3 Fluorescence anisotropy of DPH and TMA-DPH KB V20C (resistant) and parental KB (sensitive) cells Inhibits efflux pumps in KB V20C (Kwon et al., 2008)
Relaxes the hydrophobic membrane core Re Fluorescence anisotropy of DPH Brain mitochondrial membrane from male Wistar rats Protects rat brain against cerebral ischemia/reperfusion injury (Zhou et al., 2006)
Relaxes the hydrophobic membrane core Rg1 Fluorescence anisotropy of DPH Old cortical cells from Wistar rats Exerts anti-aging action (Li and Zhang, 1997)
Relaxes the hydrophobic membrane core Korean red ginseng (Rb1, Rg1, Re, Rb2) Fluorescence anisotropy of DPH Candida Albicans Disrupts the fungal membrane (Sung and Lee, 2008a)
Reduces the segmental chain mobility of the spin-labeled eggPC Rc Electron spin resonance MultiLamellar Vesicles (MLVs) containing eggPC Exhibits agglutinability toward eggPC vesicles (Fukuda et al., 1987)
Reduces the segmental mobility of the spin-labeled eggPC Rb2 Electron spin resonance MLVs containing eggPC No agglutinability toward eggPC vesicles (Fukuda et al., 1987)
Interaction with rafts
Reorganizes lipid rafts Rp1 Detergent-Resistant membrane (DRM), immunofluorescence GM-1 staining OVCAR-8 (sensitive), NCI/ADR-RES cells (resistant) Redistributes raft-associated MDR-1 protein, enhances doxorubicin accumulation in drug-resistant cells (Yun et al., 2013)
Disrupts the integrity of lipid rafts Rg3 DRM, immunocytochemistry flotillin-1 staining CHO cells, mouse primary neurons, brains from a mouse model of Alzheimer’s disease Reduces the association of presenilin 1 (PS1) fragments with lipid rafts, inhibits λ-secretase activity
Decreases amyloid-β (Aβ) levels
(Kang et al., 2013)
Reduces cholesterol and lipid raft levels Rh2 Amplex Red Cholesterol Assay Kit, immunofluorescence GM-1 staining Mouse primary neurons Reduces Aβ secretion, amyloid precursor protein (APP) endocytosis, improves learning and memory function in Alzheimer’s disease (Qiu et al., 2014)
Reduces lipid rafts and caveolae levels, increases their internalization Rh2 Immunofluorescence GM-1 and caveolin-1 staining, DRM A431, MBA-MB-231, PC3, HEK293 cells Inactivates raft-associated Akt signaling and induces cancer cell apoptosis (Park et al., 2010)
Disrupts the integrity of lipid rafts Rb2, Rc, Rd Re, Rf, Rg1, Rg2, Rh2, PPD Detergent-resistant membrane, immunofluorescence caveolae staining HeLa cervical carcinoma cells Activates death receptors and induces cancer cell apoptosis (Kang et al., 2013)
Disrupts the integrity of lipid rafts PPD Immunofluorescence SM and CHOL staining, western blot of lipid raft-associated proteins (IGF-1R, P-Akt) K562, HT29 cells, K562-xenografted BALB/c nude mice Activates neutral SMase 2 and induces cancer cell apoptosis, reduces tumor volumes in xenograft mouse models (Park et al., 2013)
Membrane permeabilization and pore formation
Disturbs osmotic behavior of liposomes with or without Chol Rb1 Absorbance measurements MLVs composed of eggPC, PA with or without Chol Induces liposomal membrane permeability (Yu et al., 1985)
Disrupts the fungal membrane Korean red ginseng (Rb1, Rg1, Re, Rb2) Colony forming units (CFUs), fluorescence anisotropy of DPH Candida albicans Decreases membrane potential and exerts antifungal effects (Sung and Lee, 2008a)
Disrupts the bacterial membrane Korean red ginseng (Rb1, Rg1, Re, Rb2) Calcein release in liposome, colony forming units Liposome composed of PC/PG (1:1), Staphylococcus aureus, S. epidermidis, Salmonella typhimurium Enhances kanamycin activity and exerts antibacterial effects (Sung and Lee, 2008a)
Forms membrane pore Rh2, Rg3 Absorbance of the supernatant Red blood cells Induces hemolysis (Li and Liu, 2008)
Permeabilizes the lysosomal membrane Octyl ester Rh2 derivative Acridine orange relocation HepG2 liver cells Releases cathepsin from lysosomes to the cytosol compartment, induces cancer cell apoptosis (Chen et al., 2016)
Disrupts the fungal membrane Rg2, Rg3, Rg6, F4, Rg5, Rk1 Minimal fungicidal concentration (MFC) Epidermophyton floccosum, Trichophyton rubrum, T. mentagrophytes Decreases membrane potential and exhibit antifungal effects (Xue et al., 2017)
Disrupts the bacterial membrane Rg2, Rg3, Rg6, F4, Rg5, Rk1 Minimal bactericidal concentration (MBC), cell constituents released into cell suspension Fusobacterium nucleatum, Clostridium perfringens, Porphyromonas gingivalis Decreases the membrane potential and exerts antibacterial effects (Xue et al., 2017)
Interaction with membrane proteins
Decreases the activity of raft-associated Akt PPD DRM U87 MG glioma cells Enhances the chemotoxicity of paclitaxel or vinblastine (Liu et al., 2011)
Increases the activity of raft-associated Akt PPD DRM N2a neuroblastoma cells Attenuates the excitotoxicity of N-methyl-D- aspartate (Liu et al., 2011)
Interacts with the 5-HT3A receptor and the human Kv1.4 channel Rg3 Ligand-gated ion currents measured via two-electrode voltage clamp technique, site-directed mutagenesis Xenopus laevis oocytes Inhibits 5-HT3A receptor-mediated ion currents and K+ currents flowing through the human Kv1.4 channel (Lee et al., 2004; Lee et al., 2008)
Interacts with the NMDA receptor Rg3, Rh2 Ligand-gated ion currents measured via two-electrode voltage clamp technique Cultured rat hippocampal neurons Antagonizes NMDA receptors (Kim et al., 2004; Lee et al., 2006)
Interacts with the NorA efflux pump Rh2 In silico molecular docking, rhodamine 123 retention assay S. aureus in vivo, S. aureus-infected peritonitis mice Promotes ciprofloxacin accumulation (Zhang et al., 2014)
Interacts with Na+/K+ ATPase PPD, Rh2, Rg3 Measurement of inorganic phosphate liberated from ATP and molecular modeling and docking Na+/K+-ATPase from the porcine cerebral cortex Inhibits Na+/K+ ATPase activity, exerts cardiac therapeutic effects (Chen et al., 2009)
Binds to the P-gp efflux pump Rg3 Rhodamine 123 retention assay and competition assay with [3H]azidopinen for binding to P-gp Multidrug-resistant P388/DOX cells Blocks drug efflux and enhances anticancer drug accumulation (Kim et al., 2003)
ROS production
Attenuates lipid peroxidation Re Antioxidant enzymes and measurement of reactive oxygen species Ischemic brain tissues of male Wistar rats Protects rat brain against cerebral ischemia/reperfusion injury (Zhou et al., 2006)
Inhibits mitochondrial permeability transition by free radical scavenging action Rg3 ROS measurements Isolated rat brain mitochondria Exerts a neuroprotective effect after cerebral ischemia (Tian et al., 2009)
Inhibits hydroxyl radical formation Rd ROS measurements Rat model of focal cerebral ischemia Exerts neuroprotection in transient focal ischemia (Ye et al., 2011a)
Inhibits lipid peroxidation Rb1, Rg1 ROS measurements Rat liver and brain microsomes Prevents cardiac ischemia (Deng and Zhang, 1991)
Exerts anti-oxidative effects Rc > Rb1 and Re > Rd > R1 > Rg1 > Rb3 > Rh1 Measurement of the absorbance of erythrocyte supernatant 2-amidinopropane hydrochloride
-induced hemolysis of erythrocytes
Reduces hemolysis (Liu et al., 2003)
Exerts pro-oxidative effects Rh2, Rg3 ROS measurements Jurkat leukemia cells Induces cancer cell apoptosis (Xia et al., 2017)
Exerts pro-oxidative effects Rh4 ROS measurements Human colorectal cancer xenograft mouse model Inhibits tumor growth (Wu et al., 2018)

Structural Diversity of Ginsenosides

The structural diversity of ginsenosides is mainly a consequence of the high variety of sugar chains connected to different aglycone backbones. Hundreds of different ginsenosides have been reported; however, describing these is not within the scope of this review. For a detailed review on the structural variety of Panax L. species, including all ginsenosides reported up to 2012, readers should refer to (Qi et al., 2011; Yang et al., 2014). In general, based on the structure of aglycone, ginsenosides can be classified into three different types, dammarane-, oleanane-, and ocotillol-types (He et al., 2018). The dammaranne type includes 20-S-protopanaxadiols (PPD) and 20-S protopanaxatriols (PPT) which share a four-ring hydrophobic steroid-like structure with sugar moieties, but differ in the carbohydrate moieties at C3, C6, and C20. In the PPD group such as Rb1, Rb2, Rb3, Rc, Rd, Rg3, Rh2, and compound K, sugar residues are attached to the hydroxyl group at C-3 and/or C-20, while in the PPT group, such as Re, Rf, Rg1, Rg2, and Rh1, sugar moieties are attached to the hydroxyl group at C-6 and/or C-20 ( Figure 1 ). Minor ginsenosides include ocotillo-type (F11) oleanane-type (Ro) ginsenosides, and other isolated compounds can be classified as modified C-20 side-chain ginsenosides (Rh4, Rg5) (Qi et al., 2011). An older classification of ginsenosides was based on their chromatographical profile, which has contributed to their current nomenclature (Ginsenoside Rb1, Rb2, Rc,…) (Yang et al., 2014).

Figure 1.

Figure 1

Chemical structure of main ginsenosides discussed in this review (Qi et al., 2011). Represented lipids are, from left to right, glycerophospholipids (phosphatidylcholine), sphingolipids (sphingomyelin, glycosphingolipids), sterols (cholesterol).

Interaction With Amphiphilic Molecules and Assembly into Nanostructures

Saponins are amphiphilic molecules, and can accumulate at hydrophobic/hydrophilic interfaces and self-aggregate above a certain concentration (critical micelle concentration; purified Quillaja saponins cmc (0.025wt%) (Israelachvili et al., 1977). Those properties provide the etymological background for the name “saponin” (“sapo” latin for soap), which solubilize hydrophobic molecules in aqueous solution and have similar properties to other detergents. Specific aggregation of saponins with phospholipids and cholesterol can lead to the formation of nanoparticles in aqueous solution, which can be used as carriers for drugs. Those football-shaped nanoparticles, named immunostimulating complexes (ISCOMs), can enhance the immune response toward certain antigens (Morein et al., 1987). Notably, ginsenosides have the potential to induce the formation of similar nanoparticles and could thus be used as nanocarriers for vaccines or potential anticancer drugs. More specifically, ginsenosides Ro, Rb1, and Rg1 are able to form nanoscopic aggregates in solution when combined with glucuronic acid and other saponins (Xiong et al., 2008). Ginsenoside Ro forms stable nanoscopic structures of vesicular shape. Rb1 forms worm-like and spherical micelles, whereby a higher number of sugars in the ginsenoside increases the number of binding sites between those constructs (Song et al., 2009; Dai et al., 2012; Dai et al., 2013). Red ginseng saponins extracted using an ethanol and water procedure from red ginseng roots (Wang et al., 1979) have been shown to build nanoscopic aggregates or ginsomes in the presence of cholesterol and phospholipids. Ginsomes can enhance immune responses in mice and are promising candidates for nanoparticle carriers in vaccines (Song et al., 2009).

Ginsenoside-Membrane Interactions

Effect of Ginsenoside Structure on Membrane Binding Property

Ginsenosides, as well as phospholipids, can be characterized as amphiphilic self-aggregating molecules. The amphiphilic character of ginsenosides permits their adsorption or insertion into lipid bilayers, in which the hydrophilic sugar moiety of saponins interacts with the interfacial part of the membrane. The membrane interface contains mainly polar headgroups, comprising osidic residues from numerous glycolipids and glycoproteins, with which the osidic part of the saponin can form intramolecular hydrogen bonds. Conversely, the steroid or triterpenoid part interacts with the membrane hydrophobic core (Keukens et al., 1995). The importance of the sugar moiety for the membrane-associated effects is highlighted by the fact that the binding of protopanaxadiol and protopanaxatriol type ginsenosides to liposomes depends inversely on the amount of sugar residues. This suggests that the higher the number of polar residues, the lower the level of binding (Hou et al., 2013). Moreover, Fukuda et al. reported that ginsenoside-Rc, having an α-L-arabinofuranose residue, exhibits remarkable agglutinability toward egg yolk phosphatidylcholine vesicles (Fukuda et al., 1985). Conversely, other saponins (Rb1, Rb2, Rd, Re, and Rg2) lack this characteristic sugar residue and present less or no agglutinability. Interaction was also found to depend on phospholipid headgroups as ginsenoside Rc interacted strongly with egg phosphatidylcholine vesicles but only slightly with egg phosphatidylethanolamine, egg phosphatidic acid, phosphatidylserine, and sphingomyelin from bovine brain. Regarding the polar sugar residues, the amount, position, type, polarity, and three-dimensional organization are important for membrane binding (Keukens et al., 1995; Hou et al., 2013; Lorent et al., 2013; Lorent J. et al., 2014).

Besides the sugar residues, the hydrophobic part of saponins is important for their binding and permeabilizing activity (Lorent J. et al., 2014; Korchowiec et al., 2015; Sudji et al., 2015), and is usually attributed to their interactions with membrane sterols. Protopanaxadiol ginsenoside-Rc interacted more efficiently with membranes composed of short or unsaturated fatty acyl chains than with those composed of saturated fatty acids (Fukuda et al., 1985). Moreover, we recently showed that cholesterol, in contrast to sphingomyelin, delays the cytotoxicity of Rh2 in human monocytic leukemia U937 cells (Verstraeten et al., 2018). This observation has been supported by a large panel of biophysical approaches on lipid monolayers or Large Unilamellar Vesicles (LUVs) (Verstraeten et al., 2019). In summary, ginsenoside membrane binding depends largely on the sugar residues, but also on the aglycone, membrane phospholipid headgroups, the unsaturation of acyl chains, and sterol content.

Effect on Dynamic Membrane Properties

In addition to structural considerations relating to the interaction between ginsenosides and membrane components, membranes can be defined by their collective and dynamic properties ( Figure 2 ), which ultimately determine the diffusive properties of all membrane components, including exogenous ginsenoside-like substances. Membranes with a high molar ratio of cholesterol, saturated phospholipids, and sphingomyelin are tightly packed and thereby restrict lipid and protein diffusion (Barenholz, 2004; Leonard et al., 2018). Conversely, membranes with a high percentage of unsaturated phospholipids and a low cholesterol content are disordered, which enables the faster diffusion of intrinsic molecules (Filippov et al., 2007). Several signaling pathways depend on the packing of lipid membranes; therefore, a transient change in lipid membrane dynamics induced by xenobiotics can have substantial consequences on cellular physiology. Several saponins have a large influence on membrane dynamics and, thus, signaling (Lorent J. H. et al., 2014). A broad variety of protopanaxadiol and protopanaxatriol-type ginsenosides (Rb2, Rc, Rd Re, Rf, Rg1, Rg2, and Rh2) can reduce membrane packing at the interface of HeLa cell membranes (Yi et al., 2009). The aglycone protopanaxadiol can also decrease membrane packing; hence, this activity is not related to the sugar moieties (Yi et al., 2009). Insertion into the lipid bilayer reduces the mobility of phosphatidylcholine. In melanoma cells, Rh2 decreases membrane fluidity as determined by diphenylhexatriene (DPH) fluorescence anisotropy; however, no change in fluorescence is observed with trimethylammonium diphenylhexatriene (TMA-DPH), suggesting that only the inner hydrophobic core is affected (Ota et al., 1987; Jiang et al., 2010). Ginsenoside Rg3 increases the fluorescence anisotropy of DPH and TMA-DPH in multidrug-resistant KB V20 cells but not in the parental KB cell, indicating a selective effect on cancer cell membranes (Kwon et al., 2008). In bovine adrenal chromaffin cells, Rg3 increases the fluorescence anisotropy of DPH, leading to the inhibition of Na+ and Ca2+ channel activity, suggesting relationship between membrane properties and signaling (Tachikawa et al., 2001). Ginsenoside Re increases fluidity of mitochondrial membrane of brain cells after cerebral ischemia injuries in rats (DPH anisotropy) (Zhou et al., 2006). In addition, an extract of Korean red ginseng could markedly reduce DPH fluorescence anisotropy in Candida albicans, suggesting that its antifungal activity is related to membrane activity (Sung and Lee, 2008a; Sung and Lee, 2008b). Finally, we recently showed that Rh2 (60 µM) compacts the hydrophobic core of the lipid bilayer (DPH anisotropy) and relaxes the interfacial packaging of the phospholipid polar head (TMA-DPH anisotropy) in U937 cells (Verstraeten et al., 2018). Accordingly, by measuring the generalized polarization (GPex) of Laurdan and the anisotropy of DPH, we observed that liposomal membrane fluidity is decreased at a low ginsenoside Rh2/lipid ratio (0.4) in the presence of egg sphingomyelin and the absence of cholesterol (Verstraeten et al., 2018). Finally, the effects on membrane packing reflect the efficient insertion and interaction of ginsenosides with cellular membranes, which seem to depend largely on the cell type and lipid composition.

Figure 2.

Figure 2

From molecular to cellular and biological effects induced by the interaction of ginsenosides with lipids.

Effect on Membrane Lateral Organization

In addition to the average lipid packing of headgroups and the hydrophobic core, cellular membranes display lateral heterogeneity in those parameters, reflected by lateral domains (Sezgin et al., 2017). Lipid rafts are cholesterol- and sphingolipid-enriched membrane nanodomains that facilitate protein signaling via the recruitment of specific proteins (Lorent et al., 2017). Their disruption may impact several signaling pathways or protein transport (Yi et al., 2009; Diaz-Rohrer et al., 2014). Ginsenosides appear to interfere with the formation of rafts, changing their properties. For example, Rp1 modulates lipid raft formation and inactivates the drug efflux pump P-glycoprotein (P-gp), leading to the accumulation of doxorubicin in doxorubicin-resistant cells (Yun et al., 2013). After 6 h, Rg3 (50 µM) has been found to reduce Aβ levels in cultured primary neurons and in the brains of mice models of Alzheimer’s disease by decreasing the association of presenilin-1 (PS1) with lipid rafts and inhibiting Υ-secretase activity (Kang et al., 2013). The effect on cultured primary neurons was already observed at 10 µM. Rh2 can also prevent Alzheimer’s disease symptoms by promoting nonamyloidogenic cleavage of amyloid precursor protein (APP) via a cholesterol and lipid raft-dependent pathway (Qiu et al., 2014). In addition, Rh2 has been reported to disrupt lipid rafts leading to apoptosis, either by oligomerization of the FAS death receptor in human cervical cancer HeLa cells (Yi et al., 2009) or by inactivation of the serine/threonine kinase Akt in human epidermoid carcinoma A431 and breast cancer MBA-MB-231 cells (Yi et al., 2009; Park et al., 2010). In contrast, another study showed that membrane cholesterol depletion suppresses Rh2-dependent dendrite formation in melanoma cells, without affecting lipid rafts (Jiang et al., 2010). Interestingly, results suggest that ginsenoside activity is cell-type specific. Indeed, Akt activity was decreased in lipid rafts of the glioma cell line U87 MG but increased in neuroblastoma N2a cells by 20S-protopanaxadiol through the regulation of raft-associated dephosphorylation. As 20S-protopanaxadiol has a chemical structure similar to that of cholesterol, this ginsenoside may intercalate into lipid rafts, leading to changes in the membrane microenvironment (Liu et al., 2011). The raft-disrupting ability of protopanaxadiol has been proposed to induce the activation of neutral sphingomyelinase and the successive transformation of sphingomyelin into pro-apoptotic ceramide (Park et al., 2013).

Pore Formation

In general, pore formation by saponins depends on the interaction with cholesterol and phospholipids, and the resulting three-dimensional aggregates that form in the membrane (Keukens et al., 1995; Lorent et al., 2013). However, cholesterol is not necessary for protopanaxadiol Rb1-induced liposomal membrane permeability but suppresses its activity, whereas protopanaxatriol Rg1 does not induce membrane permeability (Yu et al., 1985). This differs from observations with other saponins, whose pore forming abilities rely on the presence of membrane cholesterol (Bangham et al., 1962; Lorent et al., 2013).

Ginsenosides Rh2 and Rg3 are effective at forming pores in red blood cells, and thereby inducing hemolysis. Conversely, numerous ginsenosides (Rc>Rd>Re - Rb1>Rg1 Rh1>Rb3 - Rg2 - R1 - F11 - PPT) can protect erythrocytes against heme-induced hemolysis (Li and Liu, 2008). These results indicate that a sugar moiety at C-20 and a hydroxyl group at C-3 play key roles in the protective effects of protopanaxadiol and protopanaxatriol, respectively (Li and Liu, 2008). Hemolytic activity does not seem to be a common feature among ginsenosides, which makes them interesting pharmacophores because of their reduced toxicity compared to other saponins. Using calcein-filled liposomes, we found that ginsenoside Rh2 induces membrane permeability in LUV containing egg sphingomyelin, and that this is reduced by cholesterol (Verstraeten et al., 2019). This result appears controversial, given that red blood cell membranes are particularly enriched in cholesterol (Wolkers et al., 2002; Deleu et al., 2014). However, we do not exclude the influence of membrane organization or the importance of other lipids, such as phosphatidylcholine in the membrane activity of Rh2. In addition, it should be noted that liposomes have some limitations, as they do not capture the full complexity of biological membranes, such as membrane asymmetry and the large number of diverse membrane proteins. The effects of an extract of red ginseng root (Panax ginseng C.A. Meyer) (Asian or Korean ginseng) on C. albicans also seem to be related to pore formation in the cellular membrane (Sung and Lee, 2008a).

Direct Interaction With Membrane Proteins

Ginsenosides can interact with the plasma membrane, changing its dynamic and diverse cell signaling. If lipids can be considered as the main target, proteins embedded into the membrane, such as voltage-dependent or ligand-gated ion channels or pumps including the P-gp efflux pump (Nah, 2014) can also be affected directly or through an indirect effect on the biophysical membrane properties. Rg3 can interfere with the activity of ion channels, including human Kv1.4 channel and 5-hydroxytryptamine receptor type 3 (5-HT3A) (Lee et al., 2004). Rg3 inhibits 5-HT3A receptor channel activity by interacting with residues V291, F292, and I295 in the channel-gating region of transmembrane domain 2 (Lee et al., 2007; Lee et al., 2009). Moreover, in cultured hippocampal neurons, the activation of glutamate (NMDA) receptors is attenuated by ginsenoside Rh2 and Rg3 via a competitive interaction with its polyamine- or glycine-binding site, respectively (Kim S. et al., 2004; Lee et al., 2006). A comparative study showed that protopanaxadiol-based (Rd, Rg3, Rh2, F2, and compound K), but not protopanaxatriol-based (Rh1, F1, and Rg1) ginsenosides inhibit the sodium-glucose cotransporter (SGLT1). This suggested that the sugar moieties attached to the C-6 position of the dammarane structure may interfere in the affinity for this cotransporter (Gao et al., 2017). Consistent with this, Chen et al. (2009) showed that ginsenosides with sugar moieties attached to the C-3 position (such as PPD, Rh2, and Rg3) inhibit membrane-bound Na+/K+ ATPase activity (Chen et al., 2009). However, this inhibition is reduced or abolished when a monosaccharide is linked to the C-6 or C-20 position of ginsenoside (Chen et al., 2009).

Membrane Antioxidant Effects

Plasma membranes have an asymmetric lipid distribution, whereby the content of unsaturated acyl chains is higher in the inner leaflet compared with the outer leaflet (Verkleij et al., 1973; Li et al., 2016). This reduces membrane packing and increases the efficiency of protein insertion (Lorent et al., 2017). However, under high oxidative stress, reactive oxygen species (ROS) can oxidize polyunsaturated lipids. This can subsequently induce a radical chain reaction leading to protein oxidation, cellular damage, and signal induction, which can promote the development of cancer, atherosclerosis, and neurodegenerative diseases (Sultana et al., 2013; Tanaka et al., 2017). Some types of ginsenosides have demonstrated a high potential for antioxidant activity and since they efficiently insert into membranes, it is reasonable to assume that their antioxidant activity targets cellular membranes. This is supported by the finding that many ginsenosides exhibit antioxidative properties, which are mainly related to the suppression of lipid peroxidation products, especially in the context of brain and myocardial injury (Zhou et al., 2006; Tian et al., 2009; Ye et al., 2011a). In a rat model of focal cerebral ischemia, Rd at concentration ranging from 0.1 to 200 mg/kg given in intraperitoneally 30 min before middle cerebral artery occlusion was found to attenuate lipid peroxidation and neuronal oxidative damage by decreasing the formation of major end-products of oxidation of polyunsaturated fatty acids (Ye et al., 2011b). Rb1 and Rg1 exhibited neuroprotective effects and prevented cardiac ischemia via the reduction of hydrogen peroxide and hydroxyl radicals (Deng and Zhang, 1991). Regarding the structure antioxidant-activity relationship of ginsenosides, sugar moieties at position C-20 or C-6 exert antioxidant activity. The order of antioxidative ability is as follows: Rc > Rb1 and Re > Rd > R1 > Rg1 > Rb3 > Rh1 (Liu et al., 2003). Conversely, the absence of sugar moieties at the C-20 position leads to pro-oxidant activity. This may be associated with the observation that ginsenosides 24 h incubation of Jurkat cells or colorectal cancer cells with µM concentrations of Rh2, Rh4, and Rg3 induce apoptosis via the formation of radical species and depolarization of the mitochondrial membrane potential (Xia et al., 2017; Wu et al., 2018). Those results highlight the complex behavior of ginsenosides under oxidative stress.

Potential Use of Ginsenosides as Anticancer Agents

Total ginsenosides of Chinese ginseng (50 µg/ml for 24 h) showed capacity to induce cell cycle arrest and apoptosis on colorectal carcinoma HT-29 cells (Li et al., 2018). Studies on individual ginsenosides revealed the anticarcinogenic effects resulted from different mechanisms including anti-angiogenic effects (Yue et al., 2006; Yue et al., 2007) which lead to inhibition of tumor growth and metastasis (Nag et al., 2012). Some of these mechanisms may be related to their membrane activities, including alteration of lipid raft organization, pore formation, and modulation of ROS production. In addition, some ginsenosides inhibit drug efflux pumps, which can enhance the activity of conventional chemotherapeutic agents.

Ginsenosides Affect Lipid Raft Organization

The cell membrane, especially lipid rafts, has continued to attract attention as a key factor involved in tumorigenesis. Lipid rafts serve as platforms for a number of cellular pathways related to cell survival, proliferation, and apoptosis, which are often altered in cancer cells (Mollinedo and Gajate, 2015). Consequently, it may be of great advantage to modulate these domains and associated-pathways by membrane active compounds. In this regard, several studies have demonstrated that ginsenosides Rg3 or Rh2 interfere with lipid rafts and induce antiproliferative and apoptotic effects in various cancer cells (Kim H. S. et al., 2004; Zhang et al., 2013; Huang et al., 2016). For example, Rh2 blocks the growth of glioblastomas through the inhibition of receptor-tyrosine kinase EGFR and PI3K/Akt signaling, which may be associated with lipid rafts (Li et al., 2014; Li et al., 2015).

Ginsenosides Interact With ROS

The regulation of oxidative stress is essential in both tumor growth, metastasis, and responses to anticancer therapies. At low levels, ROS may contribute to tumor emergence either through signaling molecules or by promoting DNA mutation. At high levels under aberrant metabolism and signaling in cancer cells, ROS promote cell death and induce severe cellular damage. To overcome this, cancer cells possess antioxidant defense mechanisms to reduce ROS levels, even if this level remains high compared to normal cells (Gorrini et al., 2013). Thus, increasing oxidative stress through the generation of ROS may be an efficient way for targeted therapies to kill cancer cells. The mechanism underlying the anticancer activities of ginsenosides mediated by ROS depend on the specific type of cancer cells involved and the ginsenoside structure. Ginsenosides with sugar moieties at position C-20 or C-6 can mediate their antioxidant action through free radical scavenging to prevent tumor initiation. Conversely, ginsenosides with no sugar moieties at the C-20 position may generate ROS to promote apoptosis during tumor progression, invasion, and metastasis. For a detailed review on the role of ROS in anticancer therapy with ginsenosides, the reader is referred to (Sodrul et al., 2018).

Ginsenosides Inhibit Efflux Pumps

Moreover, the anticancer potential of ginsenosides may result from their ability to inhibit efflux pumps, such as P-gp. P-gp overexpression is responsible for the development of multidrug resistance, which leads to the failure of chemotherapy in patients with cancer. Several ginsenosides inhibit P-gp and thus promote the chemotherapeutic activity of drugs against cancer cells (Kim et al., 2014). Rg3 inhibits P-gp activity by decreasing membrane fluidity in human carcinoma VCR-resistant KB V20C fibroblasts (Kim et al., 2003; Kwon et al., 2008). Rp1 redistributes lipid rafts resulting in the relocalization and inhibition of P-gp (Yun et al., 2013). Finally, Rg5 interacts and reverses P-gp efflux pump activity, as demonstrated by molecular docking analyses (Feng et al., 2020).

Ginsenosides Enhance the Activity of Conventional Chemotherapeutic Agents

The combined application of ginsenosides and conventional chemotherapeutic agents could offer a promising treatment strategy for patients with cancer. Ginsenoside Rh2 (10 µM) and cisplatin (2 mg/kg) act synergistically to enhance the inhibition of human ovarian tumor cell growth in nude mice (Kikuchi et al., 1991). In combination with the alkylating agent cyclophosphamide, ginsenosides Rg3 and Rh2 decrease tumor growth in mice (Nakhjavani et al., 2019). Beside their own anticancer activities, it is tempting to speculate that ginsenosides could improve the antitumoral activity of chemotherapeutic agents through an increased membrane permeability and decreased efflux.

Restriction as Anticancer Agents

Currently, saponins are not used as chemotherapeutic agents due to their intrinsic hemolytic activity and poor bioavailability, resulting from their low aqueous solubility, instability in the gastrointestinal tract, and extensive metabolism in the body. Nevertheless, some saponins have shown low or no hemolytic effects, depending on their chemical structure (Namba et al., 1973). Re, Rh1, and Rh2 demonstrate adjuvant potential with low hemolytic activity (Sun et al., 2005; Sun et al., 2006; Yang et al., 2007). Numerous drug delivery systems, such as liposomes or nanostructures, have been developed to overcome the rapid plasma elimination of ginsenosides and to increase their solubility, leading to improved antiproliferative effect while preventing hemolytic activity (Kim et al., 2018). Indeed, Rh2-loaded methoxy poly(ethylene glycol)-poly(lactide) (mPEG-PLA) liposomes (Rh2-PLP) suppress tumor growth in HepG2-xenografted mice without any significant toxicity (Xu et al., 2015). Ginsenoside compound K encapsulated in phosphatidylcholine and phosphatidylethanolamine polyethylene glycol (PEG) enhances solubility and oral bioavailability compared to free compound K. This micellar system improves the antitumor effects of ginsenoside, including cell-cycle arrest, and decreases xenograft tumor growth in mice with low toxicity (Jin et al., 2018). In addition, treatment with G-Rg3 bile salt-phosphatidylcholine-based mixed micelle systems did not induce hemolysis in erythrocytes and demonstrated higher antiproliferative activity against tumor cells compared to free Rg3 (Yu et al., 2015). Finally, a new drug-delivery system based on highly porous graphene treated with ginsenoside Rh2 has been recently generated and shown to improve their anticancer activities (Zare-Zardini et al., 2018).

Potential Use of Ginsenosides Against Invasive Microorganisms

Fungi

Many saponins have demonstrated antifungal properties, functioning in host chemical defenses to protect plants from fungal invasion (Morrissey and Osbourn, 1999). The major mechanism underlying this effect is the formation of complexes with membrane ergosterol, the main sterol of fungi, leading to loss of membrane integrity (Keukens et al., 1995). The importance of ergosterol for saponin activity is emphasized by the isolation of insensitive mutants (Fusarium solani) to saponin due to their low sterol content (Defago and Kern, 1983). Fungi also counteract saponin activity by producing saponin-detoxifying enzymes. Ginseng root pathogens, Pseudogymnoascus destructans and Pythium irregulare, hydrolyze monosaccharide moieties attached to the C-3 and C-20 position of PPD-type ginsenoside by extracellular glycosidase, rendering them resistant to ginsenoside toxicity (Yousef and Bernards, 2006; Zhao et al., 2012). Consistent with this, removal of the sugar chain attached to the C-3 position has been shown to restrict the membrane binding of saponin to 3β-hydroxyl sterols (Kazan and Gardiner, 2017). The position and number of ginsenoside sugar moieties also influence the antifungal activity. Indeed, regarding the position of sugar moieties, the protopanaxatriol-type ginsenoside fraction (PPT-GF; Re, Rg1) from the roots of Panax ginseng C.A. Meyer (Asian or Korean ginseng) demonstrated higher growth inhibition against five ginseng non-pathogens compared to the protopanaxadiol-type ginsenoside fraction (PPD-GF; Rb2, Rc, Rd) (Zhao et al., 2012). The antifungal activity of ginsenosides is negatively correlated with the number of sugar moieties. Fungal membranes are disrupted to a greater extent after exposure to less polar ginsenosides (ginsenoside-Rk3, -Rh4, -Rh5) compared to polar ginsenosides (notoginsenodise-R1, ginsenoside Rg1, -Re, Rb2, Rd). This may be because lower polar ginsenosides interact in a larger extent with fungal membranes. Mechanistically, the interaction between ginsenosides isolated from Korean red ginseng and the Candida albicans membrane decreased DPH fluorescence anisotropy and disrupted the structure of the cell membrane (Sung and Lee, 2008a). Interestingly, plant cells contain phytosterols such as campesterol, β-sitosterol, and stigmasterol in their membranes, whereas fungal plant pathogens contain ergosterol. This suggests that targeting fungal sterols via ginsenoside synthesis may be an effective and non-toxic host defense strategy for plants to counteract fungal infections (Kazan and Gardiner, 2017).

Bacteria

The overuse of antibiotics has led to the development of bacterial resistance, resulting in an increased interest in alternative therapies, particularly in the therapeutic use of plant products. Plants have developed multiple defense mechanisms against both fungal and bacterial invasions involving the synthesis of saponins. Ginseng has demonstrated antibacterial effects against pathogenic Gram-positive and Gram-negative bacteria (Kachur and Suntres, 2016). As noted with regards to their antifungal activity, less polar ginsenosides (-Rg2, -Rg3, -Rg6, -F4, -Rg5, and –Rk1) present higher antimicrobial activity against three bacterial species (Fusobacterium nucleatum, Clostridium perfringens, and Porphyromonas gingivalis), compared with polar ginsenosides (-Rg1, -Rc, Rb2, –Rd) due to their disruptive activity on bacterial membranes (Xue et al., 2017). Interestingly, the combination of Korean red ginsenosides and kanamycin improves antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). The partial disruption of the bacterial membrane by ginsenosides is believed to facilitate the entry of kanamycin, and could explain these synergistic antibacterial effects (Sung and Lee, 2008b). In addition, non-toxic doses of ginsenoside Rh2 have been shown to enhance the susceptibilities of Staphylococcus aureus and Escherichia coli to ciprofloxacin both in vitro and in vivo (Kim et al., 2012). This effect of Rh2 could be attributed to the increased accumulation of ciprofloxacin via the inhibition of NorA efflux pump embedded in bacterial membranes (Zhang et al., 2014). Regarding this activity, ciprofloxacin-loaded polymeric micelles (poloxamer/phosphatidylcholine/cholesterol) including ginsenoside Rg3 (0.2 mg/ml) have been shown to simultaneously inhibit the P-gp efflux pump and improve ciprofloxacin solubility likely through an enhanced capacity for drug loading (Sharif Makhmal et al., 2018). Since bacterial membranes do not possess sterols, it is tempting to speculate that the antibacterial activity of ginsenosides may result from interaction with hopanoids (pentacyclic triterpenoids, structurally similar to steroids) or from other unrelated mechanisms.

Conclusions

The plasma membrane is a key target for ginsenosides, which act via the modulation of essential membrane proteins and the reorganization of lipid bilayers. This review provides an overview of different studies that have investigated the physicochemical properties of different ginsenosides and their effects on membrane components embedded in both artificial and biological membranes. We highlight the diverse effects of ginsenosides, which could result from the following attributes. First, more than 100 ginsenosides have been isolated, which differ in their amphiphilic structure, conferring them specific and multiple membrane activities. Second, membrane activities of ginsenosides seem to change depending on the cell type, which could be explained by differences in the composition of the lipid membrane between cell lines. Third, by changing membrane dynamics, a single ginsenoside may alter a range of membrane proteins, thereby altering various cell signaling pathways. Interestingly, the ability of several ginsenosides to suppress cell proliferation, induce apoptosis, and inhibit efflux pumps suggests they could represent promising candidates for drug development for the treatment of cancer, as well as bacterial and fungal infections.

Author Contributions

SV and JL collected data and wrote the manuscript with the participation from M-PM-L. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

SV is a doctoral fellow of the Télévie. This work was supported by the Belgian Fonds de la Recherche Scientifique (F.S.R-FNRS) and by ARC. We gratefully thank Jean-Luc Decout (Université Grenoble Rhone Alpes, France) for drawing chemical structures of ginsenosides.

References

  1. Bangham A. D., Horne R. W., Glauert A. M., Dingle J. T., Lucy J. A. (1962). Action of saponin on biological cell membranes. Nature 196, 952–955. 10.1038/196952a0 [DOI] [PubMed] [Google Scholar]
  2. Barenholz Y. (2004). Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. Subcell. Biochem. 37, 167–215. 10.1007/978-1-4757-5806-1_5 [DOI] [PubMed] [Google Scholar]
  3. Chen R. J., Chung T. Y., Li F. Y., Lin N. H., Tzen J. T. (2009). Effect of sugar positions in ginsenosides and their inhibitory potency on Na+/K+-ATPase activity. Acta Pharmacol. Sin. 30, 61–69. 10.1038/aps.2008.6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chen F., Zhang B., Sun Y., Xiong Z. X., Peng H., Deng Z. Y., et al. (2016). The octyl ester of ginsenoside Rh2 Induces lysosomal membrane permeabilization via Bax translocation. Nutrients 8, 1–14. 10.3390/nu8050244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dai X., Shi X., Wang Y., Qiao Y. (2012). Solubilization of saikosaponin a by ginsenoside Ro biosurfactant in aqueous solution: mesoscopic simulation. J. Colloid Interface Sci. 384, 73–80. 10.1016/j.jcis.2012.06.018 [DOI] [PubMed] [Google Scholar]
  6. Dai X., Shi X., Yin Q., Ding H., Qiao Y. (2013). Multiscale study on the interaction mechanism between ginsenoside biosurfactant and saikosaponin a. J. Colloid Interface Sci. 396, 165–172. 10.1016/j.jcis.2013.01.017 [DOI] [PubMed] [Google Scholar]
  7. Defago G., Kern H. (1983). Induction of Fusarium solani mutants insensitive to tomatine, their pathogenicity and aggressiveness to tomato fruits and pea plants. Physiol. Plant Pathol. 22, 29–37. 10.1016/S0048-4059(83)81035-2 [DOI] [Google Scholar]
  8. Deleu M., Crowet J. M., Nasir M. N., Lins L. (2014). Complementary biophysical tools to investigate lipid specificity in the interaction between bioactive molecules and the plasma membrane: A review. Biochim. Biophys. Acta 1838, 3171–3190. 10.1016/j.bbamem.2014.08.023 [DOI] [PubMed] [Google Scholar]
  9. Deng H. L., Zhang J. T. (1991). Anti-lipid peroxilative effect of ginsenoside Rb1 and Rg1. Chin. Med. J. (Engl.) 104, 395–398. [PubMed] [Google Scholar]
  10. Diaz-Rohrer B. B., Levental K. R., Simons K., Levental I. (2014). Membrane raft association is a determinant of plasma membrane localization. Proc. Natl. Acad. Sci. U. S. A. 111, 8500–8505. 10.1073/pnas.1404582111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Feng S. L., Luo H. B., Cai L., Zhang J., Wang D., Chen Y. J., et al. (2020). Ginsenoside Rg5 overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter: in vitro and in vivo study. J. Ginseng Res. 44, 247–257. 10.1016/j.jgr.2018.10.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Filippov A., Oradd G., Lindblom G. (2007). Domain formation in model membranes studied by pulsed-field gradient-NMR: the role of lipid polyunsaturation. Biophys. J. 93, 3182–3190. 10.1529/biophysj.107.111534 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fukuda K., Utsumi H., Shoji J., Hamada A. (1985). Saponins can cause the agglutination of phospholipid vesicles. Biochim. Biophys. Acta 820, 199–206. 10.1016/0005-2736(85)90113-0 [DOI] [PubMed] [Google Scholar]
  14. Fukuda K., Utsumi H., Soda S., Shoji J., Hamada A. (1987). Specific interaction of arabinose residue in ginsenoside with egg phosphatidylcholine vesicles. Biochim. Biophys. Acta 900, 267–274. 10.1016/0005-2736(87)90341-5 [DOI] [PubMed] [Google Scholar]
  15. Gao S., Kushida H., Makino T. (2017). Ginsenosides, ingredients of the root of Panax ginseng, are not substrates but inhibitors of sodium-glucose transporter 1. J. Nat. Med. 71, 131–138. 10.1007/s11418-016-1042-9 [DOI] [PubMed] [Google Scholar]
  16. Gorrini C., Harris I. S., Mak T. W. (2013). Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discovery 12, 931–947. 10.1038/nrd4002 [DOI] [PubMed] [Google Scholar]
  17. He M., Huang X., Liu S., Guo C., Xie Y., Meijer A. H., et al. (2018). The Difference between White and Red Ginseng: Variations in Ginsenosides and Immunomodulation. Planta Med. 84, 845–854. 10.1055/a-0641-6240 [DOI] [PubMed] [Google Scholar]
  18. Hou G., Niu J., Song F., Liu Z., Liu S. (2013). Studies on the interactions between ginsenosides and liposome by equilibrium dialysis combined with ultrahigh performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 923–924, 1–7. 10.1016/j.jchromb.2013.01.035 [DOI] [PubMed] [Google Scholar]
  19. Huang J., Peng K., Wang L., Wen B., Zhou L., Luo T., et al. (2016). Ginsenoside Rh2 inhibits proliferation and induces apoptosis in human leukemia cells via TNF-alpha signaling pathway. Acta Biochim. Biophys. Sin. (Shanghai) 48, 750–755. 10.1093/abbs/gmw049 [DOI] [PubMed] [Google Scholar]
  20. Israelachvili J. N., Mitchell D. J., Ninham B. W. (1977). Theory of self-assembly of lipid bilayers and vesicles. Biochim. Biophys. Acta 470, 185–201. 10.1016/0005-2736(77)90099-2 [DOI] [PubMed] [Google Scholar]
  21. Jiang Y. S., Jin Z. X., Umehara H., Ota T. (2010). Cholesterol-dependent induction of dendrite formation by ginsenoside Rh2 in cultured melanoma cells. Int. J. Mol. Med. 26, 787–793. 10.3892/ijmm_00000526 [DOI] [PubMed] [Google Scholar]
  22. Jin X., Yang Q., Cai N. (2018). Preparation of ginsenoside compound-K mixed micelles with improved retention and antitumor efficacy. Int. J. Nanomed. 13, 3827–3838. 10.2147/IJN.S167529 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kachur K., Suntres Z. E. (2016). The antimicrobial properties of ginseng and ginseng extracts. Expert. Rev. Anti. Infect. Ther. 14, 81–94. 10.1586/14787210.2016.1118345 [DOI] [PubMed] [Google Scholar]
  24. Kang M. S., Baek S. H., Chun Y. S., Moore A. Z., Landman N., Berman D., et al. (2013). Modulation of lipid kinase PI4KIIalpha activity and lipid raft association of presenilin 1 underlies gamma-secretase inhibition by ginsenoside (20S)-Rg3. J. Biol. Chem. 288, 20868–20882. 10.1074/jbc.M112.445734 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kazan K., Gardiner D. M. (2017). Targeting pathogen sterols: Defence and counterdefence? PLoS. Pathog. 13, e1006297. 10.1371/journal.ppat.1006297 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Keukens E. A., de V. T., van den Boom C., de W. P., Plasman H. H., Thiel F., et al. (1995). Molecular basis of glycoalkaloid induced membrane disruption. Biochim. Biophys. Acta 1240, 216–228. 10.1016/0005-2736(95)00186-7 [DOI] [PubMed] [Google Scholar]
  27. Kikuchi Y., Sasa H., Kita T., Hirata J., Tode T., Nagata I. (1991). Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs 2, 63–67. 10.1097/00001813-199102000-00009 [DOI] [PubMed] [Google Scholar]
  28. Kim S. W., Kwon H. Y., Chi D. W., Shim J. H., Park J. D., Lee Y. H., et al. (2003). Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem. Pharmacol. 65, 75–82. 10.1016/S0006-2952(02)01446-6 [DOI] [PubMed] [Google Scholar]
  29. Kim H. S., Lee E. H., Ko S. R., Choi K. J., Park J. H., Im D. S. (2004). Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch. Pharm. Res. 27, 429–435. 10.1007/BF02980085 [DOI] [PubMed] [Google Scholar]
  30. Kim S., Kim T., Ahn K., Park W. K., Nah S. Y., Rhim H. (2004). Ginsenoside Rg3 antagonizes NMDA receptors through a glycine modulatory site in rat cultured hippocampal neurons. Biochem. Biophys. Res. Commun. 323, 416–424. 10.1016/j.bbrc.2004.08.106 [DOI] [PubMed] [Google Scholar]
  31. Kim S. H., Ha U. S., Sohn D. W., Lee S. J., Kim H. W., Han C. H., et al. (2012). Preventive effect of ginsenoid on chronic bacterial prostatitis. J. Infect. Chemother. 18, 709–714. 10.1007/s10156-012-0406-7 [DOI] [PubMed] [Google Scholar]
  32. Kim S. S., Seong S., Kim S. Y. (2014). Synergistic effect of ginsenoside Rg3 with verapamil on the modulation of multidrug resistance in human acute myeloid leukemia cells. Oncol. Lett. 7, 1265–1269. 10.3892/ol.2014.1826 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Kim H., Lee J. H., Kim J. E., Kim Y. S., Ryu C. H., Lee H. J., et al. (2018). Micro-/nano-sized delivery systems of ginsenosides for improved systemic bioavailability. J. Ginseng. Res. 42, 361–369. 10.1016/j.jgr.2017.12.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Korchowiec B., Gorczyca M., Wojszko K., Janikowska M., Henry M., Rogalska E. (2015). Impact of two different saponins on the organization of model lipid membranes. Biochim. Biophys. Acta 1848, 1963–1973. 10.1016/j.bbamem.2015.06.007 [DOI] [PubMed] [Google Scholar]
  35. Kwon H. Y., Kim E. H., Kim S. W., Kim S. N., Park J. D., Rhee D. K. (2008). Selective toxicity of ginsenoside Rg3 on multidrug resistant cells by membrane fluidity modulation. Arch. Pharm. Res. 31, 171–177. 10.1007/s12272-001-1137-y [DOI] [PubMed] [Google Scholar]
  36. Lee B. H., Jeong S. M., Ha T. S., Park C. S., Lee J. H., Kim J. H., et al. (2004). Ginsenosides regulate ligand-gated ion channels from the outside. Mol. Cells 18, 115–121. [PubMed] [Google Scholar]
  37. Lee E., Kim S., Chung K. C., Choo M. K., Kim D. H., Nam G., et al. (2006). 20(S)-ginsenoside Rh2, a newly identified active ingredient of ginseng, inhibits NMDA receptors in cultured rat hippocampal neurons. Eur. J. Pharmacol. 536, 69–77. 10.1016/j.ejphar.2006.02.038 [DOI] [PubMed] [Google Scholar]
  38. Lee B. H., Lee J. H., Lee S. M., Jeong S. M., Yoon I. S., Lee J. H., et al. (2007). Identification of ginsenoside interaction sites in 5-HT3A receptors. Neuropharmacology 52, 1139–1150. 10.1016/j.neuropharm.2006.12.001 [DOI] [PubMed] [Google Scholar]
  39. Lee J. H., Lee B. H., Choi S. H., Yoon I. S., Pyo M. K., Shin T. J., et al. (2008). Ginsenoside Rg3 inhibits human Kv1.4 channel currents by interacting with the Lys531 residue. Mol. Pharmacol. 73, 619–626. 10.1124/mol.107.040360 [DOI] [PubMed] [Google Scholar]
  40. Lee J. H., Choi S. H., Lee B. H., Shin T. J., Pyo M. K., Hwang S. H., et al. (2009). The effects of ginsenoside Rg(3) on human Kv1.4 channel currents without the N-terminal rapid inactivation domain. Biol. Pharm. Bull. 32, 614–618. 10.1248/bpb.32.614 [DOI] [PubMed] [Google Scholar]
  41. Leonard C., Pollet H., Vermylen C., Gov N., Tyteca D., Mingeot-Leclercq M. P. (2018). Tuning of differential lipid order between submicrometric domains and surrounding membrane upon erythrocyte reshaping. Cell Physiol. Biochem. 48, 2563–2582. 10.1159/000492700 [DOI] [PubMed] [Google Scholar]
  42. Li G. X., Liu Z. Q. (2008). The protective effects of ginsenosides on human erythrocytes against hemin-induced hemolysis. Food Chem. Toxicol. 46, 886–892. 10.1016/j.fct.2007.10.020 [DOI] [PubMed] [Google Scholar]
  43. Li J. Q., Zhang J. T. (1997). [Effects of age and ginsenoside RG1 on membrane fluidity of cortical cells in rats]. Yao Xue. Xue. Bao. 32, 23–27. [PubMed] [Google Scholar]
  44. Li S., Gao Y., Ma W., Guo W., Zhou G., Cheng T., et al. (2014). EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2. Tumour. Biol. 35, 5593–5598. 10.1007/s13277-014-1739-x [DOI] [PubMed] [Google Scholar]
  45. Li S., Guo W., Gao Y., Liu Y. (2015). Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor. Tumour. Biol. 36, 2607–2612. 10.1007/s13277-014-2880-2 [DOI] [PubMed] [Google Scholar]
  46. Li G., Kim J., Huang Z., St Clair J. R., Brown D. A., London E. (2016). Efficient replacement of plasma membrane outer leaflet phospholipids and sphingolipids in cells with exogenous lipids. Proc. Natl. Acad. Sci. U. S. A. 113, 14025–14030. 10.1073/pnas.1610705113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Li T., Sun W., Dong X., Yu W., Cai J., Yuan Q., et al. (2018). Total ginsenosides of Chinese ginseng induces cell cycle arrest and apoptosis in colorectal carcinoma HT-29 cells. Oncol. Lett. 16, 4640–4648. 10.3892/ol.2018.9192 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Liu Z. Q., Luo X. Y., Liu G. Z., Chen Y. P., Wang Z. C., Sun Y. X. (2003). In vitro study of the relationship between the structure of ginsenoside and its antioxidative or prooxidative activity in free radical induced hemolysis of human erythrocytes. J. Agric. Food Chem. 51, 2555–2558. 10.1021/jf026228i [DOI] [PubMed] [Google Scholar]
  49. Liu Y., Yang G., Bu X., Liu G., Ding J., Li P., et al. (2011). Cell-type-specific regulation of raft-associated Akt signaling. Cell Death. Dis. 2, e145. 10.1038/cddis.2011.28 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Lorent J., Le Duff C. S., Quetin-Leclercq J., Mingeot-Leclercq M. P. (2013). Induction of highly curved structures in relation to membrane permeabilization and budding by the triterpenoid saponins, alpha- and delta-Hederin. J. Biol. Chem. 288, 14000–14017. 10.1074/jbc.M112.407635 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Lorent J. H., Quetin-Leclercq J., Mingeot-Leclercq M. P. (2014). The amphiphilic nature of saponins and their effects on artificial and biological membranes and potential consequences for red blood and cancer cells. Org. Biomol. Chem. 12, 8803–8822. 10.1039/C4OB01652A [DOI] [PubMed] [Google Scholar]
  52. Lorent J., Lins L., Domenech O., Quetin-Leclercq J., Brasseur R., Mingeot-Leclercq M. P. (2014). Domain formation and permeabilization induced by the saponin alpha-hederin and its aglycone hederagenin in a cholesterol-containing bilayer. Langmuir 30, 4556–4569. 10.1021/la4049902 [DOI] [PubMed] [Google Scholar]
  53. Lorent J. H., Diaz-Rohrer B., Lin X., Spring K., Gorfe A. A., Levental K. R., et al. (2017). Structural determinants and functional consequences of protein affinity for membrane rafts. Nat. Commun. 8, 1219. 10.1038/s41467-017-01328-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Mollinedo F., Gajate C. (2015). Lipid rafts as major platforms for signaling regulation in cancer. Adv. Biol. Regul. 57, 130–146. 10.1016/j.jbior.2014.10.003 [DOI] [PubMed] [Google Scholar]
  55. Morein B., Lovgren K., Hoglund S., Sundquist B. (1987). The ISCOM: an immunostimulating complex. Immunol. Today 8, 333–338. 10.1016/0167-5699(87)90008-9 [DOI] [PubMed] [Google Scholar]
  56. Morrissey J. P., Osbourn A. E. (1999). Fungal resistance to plant antibiotics as a mechanism of pathogenesis. Microbiol. Mol. Biol. Rev. 63, 708–724. 10.1128/MMBR.63.3.708-724.1999 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Nag S. A., Qin J. J., Wang W., Wang M. H., Wang H., Zhang R. (2012). Ginsenosides as anticancer agents: In vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. Front. Pharmacol. 3, 25. 10.3389/fphar.2012.00025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Nah S. Y. (2014). Ginseng ginsenoside pharmacology in the nervous system: involvement in the regulation of ion channels and receptors. Front. Physiol. 5, 98. 10.3389/fphys.2014.00098 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Nakhjavani M., Hardingham J. E., Palethorpe H. M., Tomita Y., Smith E., Price T. J., et al. (2019). Ginsenoside Rg3: potential molecular targets and therapeutic indication in metastatic breast cancer. Med. (Basel) 6, 1–20. 10.3390/medicines6010017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Namba T., Yoshizaki M., Tominori T., Kobashi K., Mitsui K. (1973). Hemolytic and its protective activity of ginseng saponins. Chem. Pharm. Bull. (Tokyo) 21, 459–461. 10.1248/cpb.21.459 [DOI] [PubMed] [Google Scholar]
  61. Ota T., Fujikawa-yamamoto K., Zong Z. P., Yamazaki M., Odashima S., Kitagawa I., et al. (1987). Plant-glycoside modulation of cell surface related to control of differentiation in cultured B16 melanoma cells. Cancer Res. 47, 3863–3867. [PubMed] [Google Scholar]
  62. Park E. K., Lee E. J., Lee S. H., Koo K. H., Sung J. Y., Hwang E. H., et al. (2010). Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt. Br. J. Pharmacol. 160, 1212–1223. 10.1111/j.1476-5381.2010.00768.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Park B., Lee Y. M., Kim J. S., Her Y., Kang J. H., Oh S. H., et al. (2013). Neutral sphingomyelinase 2 modulates cytotoxic effects of protopanaxadiol on different human cancer cells. BMC. Complement. Altern. Med. 13, 194. 10.1186/1472-6882-13-194 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Qi L. W., Wang C. Z., Yuan C. S. (2011). Ginsenosides from American ginseng: chemical and pharmacological diversity. Phytochemistry 72, 689–699. 10.1016/j.phytochem.2011.02.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Qiu J., Li W., Feng S. H., Wang M., He Z. Y. (2014). Ginsenoside Rh2 promotes nonamyloidgenic cleavage of amyloid precursor protein via a cholesterol-dependent pathway. Genet. Mol. Res. 13, 3586–3598. 10.4238/2014.May.9.2 [DOI] [PubMed] [Google Scholar]
  66. Sezgin E., Levental I., Mayor S., Eggeling C. (2017). The mystery of membrane organization: composition, regulation and roles of lipid rafts. Nat. Rev. Mol. Cell Biol. 18, 361–374. 10.1038/nrm.2017.16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Sharif Makhmal Z. B., Esfahani G., Salimi A. (2018). Permeability of ciprofloxacin-loaded polymeric micelles including ginsenoside as P-glycoprotein Inhibitor through a Caco-2 cells monolayer as an intestinal absorption model. Molecules 23, 1–15. 10.3390/molecules23081904 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Shin B. K., Kwon S. W., Park J. H. (2015). Chemical diversity of ginseng saponins from Panax ginseng. J. Ginseng Res. 39, 287–298. 10.1016/j.jgr.2014.12.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Sodrul I. M. D., Wang C., Chen X., Du J., Sun H. (2018). Role of ginsenosides in reactive oxygen species-mediated anticancer therapy. Oncotarget 9, 2931–2950. 10.18632/oncotarget.23407 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Song X., Zang L., Hu S. (2009). Amplified immune response by ginsenoside-based nanoparticles (ginsomes). Vaccine 27, 2306–2311. 10.1016/j.vaccine.2009.02.040 [DOI] [PubMed] [Google Scholar]
  71. Sudji I. R., Subburaj Y., Frenkel N., Garcia-Saez A. J., Wink M. (2015). Membrane disintegration caused by the steroid saponin digitonin Is related to the presence of cholesterol. Molecules 20, 20146–20160. 10.3390/molecules201119682 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Sultana R., Perluigi M., Butterfield D. A. (2013). Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic. Biol. Med. 62, 157–169. 10.1016/j.freeradbiomed.2012.09.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Sun H. X., Qin F., Ye Y. P. (2005). Relationship between haemolytic and adjuvant activity and structure of protopanaxadiol-type saponins from the roots of Panax notoginseng . Vaccine 23, 5533–5542. 10.1016/j.vaccine.2005.07.036 [DOI] [PubMed] [Google Scholar]
  74. Sun H. X., Chen Y., Ye Y. (2006). Ginsenoside Re and notoginsenoside R1: Immunologic adjuvants with low haemolytic effect. Chem. Biodivers. 3, 718–726. 10.1002/cbdv.200690074 [DOI] [PubMed] [Google Scholar]
  75. Sung W. S., Lee D. G. (2008. a). In vitro candidacidal action of Korean red ginseng saponins against Candida albicans . Biol. Pharm. Bull. 31, 139–142. 10.1248/bpb.31.139 [DOI] [PubMed] [Google Scholar]
  76. Sung W. S., Lee D. G. (2008. b). The combination effect of Korean red ginseng saponins with kanamycin and cefotaxime against methicillin-resistant Staphylococcus aureus . Biol. Pharm. Bull. 31, 1614–1617. 10.1248/bpb.31.1614 [DOI] [PubMed] [Google Scholar]
  77. Tachikawa E., Kudo K., Nunokawa M., Kashimoto T., Takahashi E., Kitagawa S. (2001). Characterization of ginseng saponin ginsenoside-Rg(3) inhibition of catecholamine secretion in bovine adrenal chromaffin cells. Biochem. Pharmacol. 62, 943–951. 10.1016/S0006-2952(01)00743-2 [DOI] [PubMed] [Google Scholar]
  78. Tanaka A., Yamamoto A., Murota K., Tsujiuchi T., Iwamori M., Fukushima N. (2017). Polyunsaturated fatty acids induce ovarian cancer cell death through ROS-dependent MAP kinase activation. Biochem. Biophys. Res. Commun. 493, 468–473. 10.1016/j.bbrc.2017.08.168 [DOI] [PubMed] [Google Scholar]
  79. Tian J., Zhang S., Li G., Liu Z., Xu B. (2009). 20(S)-ginsenoside Rg3, a neuroprotective agent, inhibits mitochondrial permeability transition pores in rat brain. Phytother. Res. 23, 486–491. 10.1002/ptr.2653 [DOI] [PubMed] [Google Scholar]
  80. van Meer G. (2005). Cellular lipidomics. EMBO J. 24, 3159–3165. 10.1038/sj.emboj.7600798 [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Verkleij A. J., Zwaal R. F., Roelofsen B., Comfurius P., Kastelijn D., van Deenen L. L. (1973). The asymmetric distribution of phospholipids in the human red cell membrane. A combined study using phospholipases and freeze-etch electron microscopy. Biochim. Biophys. Acta 323, 178–193. 10.1016/0005-2736(73)90143-0 [DOI] [PubMed] [Google Scholar]
  82. Verstraeten S. L., Albert M., Paquot A., Muccioli G. G., Tyteca D., Mingeot-Leclercq M. P. (2018). Membrane cholesterol delays cellular apoptosis induced by ginsenoside Rh2, a steroid saponin. Toxicol. Appl. Pharmacol. 352, 59–67. 10.1016/j.taap.2018.05.014 [DOI] [PubMed] [Google Scholar]
  83. Verstraeten S. L., Deleu M., Janikowska-Sagan M., Claereboudt E. J. S., Lins L., Tyteca D., et al. (2019). The activity of the saponin ginsenoside Rh2 is enhanced by the interaction with membrane sphingomyelin but depressed by cholesterol. Sci. Rep. 9, 7285. 10.1038/s41598-019-43674-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Wang M. Z., Gao F. Y., Zhang G. D., Zhang S. R. (1979). [Analysis of ginseng. I. The extraction and colorimetric determination of ginseng sapogenins (author’s transl)]. Yao Xue. Xue. Bao. 14, 309–315. [PubMed] [Google Scholar]
  85. Wolkers W. F., Crowe L. M., Tsvetkova N. M., Tablin F., Crowe J. H. (2002). In situ assessment of erythrocyte membrane properties during cold storage. Mol. Membr. Biol. 19, 59–65. 10.1080/09687680110103613 [DOI] [PubMed] [Google Scholar]
  86. Wu Q., Deng J., Fan D., Duan Z., Zhu C., Fu R., et al. (2018). Ginsenoside Rh4 induces apoptosis and autophagic cell death through activation of the ROS/JNK/p53 pathway in colorectal cancer cells. Biochem. Pharmacol. 148, 64–74. 10.1016/j.bcp.2017.12.004 [DOI] [PubMed] [Google Scholar]
  87. Xia T., Wang Y. N., Zhou C. X., Wu L. M., Liu Y., Zeng Q. H., et al. (2017). Ginsenoside Rh2 and Rg3 inhibit cell proliferation and induce apoptosis by increasing mitochondrial reactive oxygen species in human leukemia Jurkat cells. Mol. Med. Rep. 15, 3591–3598. 10.3892/mmr.2017.6459 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Xiong J., Guo J., Huang L., Meng B., Ping Q. (2008). Self-micelle formation and the incorporation of lipid in the formulation affect the intestinal absorption of Panax notoginseng . Int. J. Pharm. 360, 191–196. 10.1016/j.ijpharm.2008.04.016 [DOI] [PubMed] [Google Scholar]
  89. Xu L., Yu H., Yin S. Z. (2015). Liposome-based delivery systems for ginsenoside Rh2: in vitro and in vivo comparisons. J. Nanopart. Res. 17, 415. 10.1007/s11051-015-3214-z [DOI] [Google Scholar]
  90. Xue P., Yao Y., Yang X. S., Feng J., Ren G. X. (2017). Improved antimicrobial effect of ginseng extract by heat transformation. J. Ginseng Res. 41, 180–187. 10.1016/j.jgr.2016.03.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Yang Z. G., Ye Y. P., Sun H. X. (2007). Immunological adjuvant effect of ginsenoside Rh4 from the roots of Panax notoginseng on specific antibody and cellular response to ovalbumin in mice. Chem. Biodivers. 4, 232–240. 10.1002/cbdv.200790028 [DOI] [PubMed] [Google Scholar]
  92. Yang W. Z., Hu Y., Wu W. Y., Ye M., Guo D. A. (2014). Saponins in the genus Panax L. (Araliaceae): a systematic review of their chemical diversity. Phytochemistry 106, 7–24. 10.1016/j.phytochem.2014.07.012 [DOI] [PubMed] [Google Scholar]
  93. Ye R., Kong X., Yang Q., Zhang Y., Han J., Zhao G. (2011. a). Ginsenoside Rd attenuates redox imbalance and improves stroke outcome after focal cerebral ischemia in aged mice. Neuropharmacology 61, 815–824. 10.1016/j.neuropharm.2011.05.029 [DOI] [PubMed] [Google Scholar]
  94. Ye R., Yang Q., Kong X., Han J., Zhang X., Zhang Y., et al. (2011. b). Ginsenoside Rd attenuates early oxidative damage and sequential inflammatory response after transient focal ischemia in rats. Neurochem. Int. 58, 391–398. 10.1016/j.neuint.2010.12.015 [DOI] [PubMed] [Google Scholar]
  95. Yi J. S., Choo H. J., Cho B. R., Kim H. M., Kim Y. N., Ham Y. M., et al. (2009). Ginsenoside Rh2 induces ligand-independent Fas activation via lipid raft disruption. Biochem. Biophys. Res. Commun. 385, 154–159. 10.1016/j.bbrc.2009.05.028 [DOI] [PubMed] [Google Scholar]
  96. Yousef L. F., Bernards M. A. (2006). In vitro metabolism of ginsenosides by the ginseng root pathogen Pythium irregulare . Phytochemistry 67, 1740–1749. 10.1016/j.phytochem.2005.06.030 [DOI] [PubMed] [Google Scholar]
  97. Yu B. S., Kim A., Chung H. H., Yoshikawa W., Akutsu H., Kyogoku Y. (1985). Effects of purified ginseng saponins on multilamellar liposomes. Chem. Biol. Interact. 56, 303–319. 10.1016/0009-2797(85)90013-4 [DOI] [PubMed] [Google Scholar]
  98. Yu X., Xu H., Hu M., Luan X., Wang K., Fu Y., et al. (2015). Ginsenoside Rg3 bile salt-phosphatidylcholine-based mixed micelles: design, characterization, and evaluation. Chem. Pharm. Bull. (Tokyo) 63, 361–368. 10.1248/cpb.c15-00045 [DOI] [PubMed] [Google Scholar]
  99. Yue P. Y., Wong D. Y., Wu P. K., Leung P. Y., Mak N. K., Yeung H. W., et al. (2006). The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem. Pharmacol. 72, 437–445. 10.1016/j.bcp.2006.04.034 [DOI] [PubMed] [Google Scholar]
  100. Yue P. Y., Mak N. K., Cheng Y. K., Leung K. W., Ng T. B., Fan D. T., et al. (2007). Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides. Chin. Med. 2, 6. 10.1186/1749-8546-2-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Yun U. J., Lee J. H., Koo K. H., Ye S. K., Kim S. Y., Lee C. H., et al. (2013). Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition. Biochem. Pharmacol. 85, 1441–1453. 10.1016/j.bcp.2013.02.025 [DOI] [PubMed] [Google Scholar]
  102. Zare-Zardini H., Taheri-Kafrani A., Amiri A., Bordbar A. K. (2018). New generation of drug delivery systems based on ginsenoside Rh2-, Lysine- and Arginine-treated highly porous graphene for improving anticancer activity. Sci. Rep. 8, 586. 10.1038/s41598-017-18938-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Zhang Y. L., Zhang R., Xu H. L., Yu X. F., Qu S. C., Sui D. Y. (2013). 20(S)-protopanaxadiol triggers mitochondrial-mediated apoptosis in human lung adenocarcinoma A549 cells via inhibiting the PI3K/Akt signaling pathway. Am. J. Chin. Med. 41, 1137–1152. 10.1142/S0192415X13500778 [DOI] [PubMed] [Google Scholar]
  104. Zhang J., Sun Y., Wang Y., Lu M., He J., Liu J., et al. (2014). Non-antibiotic agent ginsenoside 20(S)-Rh2 enhanced the antibacterial effects of ciprofloxacin in vitro and in vivo as a potential NorA inhibitor. Eur. J. Pharmacol. 740, 277–284. 10.1016/j.ejphar.2014.07.020 [DOI] [PubMed] [Google Scholar]
  105. Zhao X., Gao J., Song C., Fang Q., Wang N., Zhao T., et al. (2012). Fungal sensitivity to and enzymatic deglycosylation of ginsenosides. Phytochemistry 78, 65–71. 10.1016/j.phytochem.2012.02.027 [DOI] [PubMed] [Google Scholar]
  106. Zhou X. M., Cao Y. L., Dou D. Q. (2006). Protective effect of ginsenoside-Re against cerebral ischemia/reperfusion damage in rats. Biol. Pharm. Bull. 29, 2502–2505. 10.1248/bpb.29.2502 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES